They influence the structural integrity and TGF-β signalling as well as modulate the immune landscape in tumors, which is in line with the simultaneous higher levels of PD-L1 responsible for the reduced frequency of tumor infiltrating lymphocytes (TILs) [27, 55–57]. The gene discussed is TGFB1; the disease is neoplasm.